8-K: Acadia Pharmaceuticals Reports Strong Q1 2025 Results, Driven by NUPLAZID and DAYBUE Growth

Acadia Pharmaceuticals announces a 19% year-over-year increase in total revenue for Q1 2025, driven by strong sales of NUPLAZID and DAYBUE, and accelerates the timeline for its COMPASS PWS Phase 3 study.

Summary

• Acadia Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
• Total revenues for Q1 2025 were $244.3 million, a 19% increase compared to Q1 2024.
• NUPLAZID net product sales reached $159.7 million, up 23% year-over-year.
• DAYBUE net product sales were $84.6 million, an 11% increase year-over-year, with a 9.5% increase in unique patients shipped.
• The company reiterates its full-year 2025 revenue guidance, including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million.
• Acadia is accelerating the timing for the COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, with topline results now expected in early Q4 2025.
• Net income for the quarter was $19.0 million, or $0.11 per common share, compared to $16.6 million, or $0.10 per common share, for the same period in 2024.
• At March 31, 2025, Acadia's cash, cash equivalents, and investment securities totaled $681.6 million, compared to $756.0 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, growth in key products, and accelerated clinical trial timelines. The reiteration of full-year guidance further reinforces the positive sentiment.

Positives

• Strong revenue growth driven by both NUPLAZID and DAYBUE.
• Increased number of unique patients receiving DAYBUE.
• Expansion of the DAYBUE field force to support broader engagement with healthcare professionals.
• Acceleration of the COMPASS PWS Phase 3 study timeline.
• Positive net income for the quarter.
• Reiteration of full-year 2025 revenue guidance.

Negatives

• Cash, cash equivalents, and investment securities decreased from $756.0 million at December 31, 2024, to $681.6 million at March 31, 2025.
• Increased R&D expenses due to the acceleration of the ACP-101 Phase 3 study timeline.

Risks

• Dependency on the continued successful commercialization of NUPLAZID and DAYBUE.
• Risks associated with clinical trials and their outcomes, including unsuccessful enrollment and negative or inconsistent results.
• Dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers, and distributors.
• Impact of competitive products and therapies.
• Ability to generate or obtain the necessary capital to fund operations.
• Ability to manage the growth and complexity of the organization.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with applicable laws and regulations.

Future Outlook

Acadia reiterates its full-year 2025 revenue guidance, including total revenues of $1.03 to $1.095 billion, NUPLAZID net product sales in the range of $650 to $690 million, and DAYBUE net product sales in the range of $380 to $405 million. R&D expense is now expected to be in the range of $330 to $350 million.

Management Comments

• Catherine Owen Adams, Chief Executive Officer, stated that 2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter.
• She noted that DAYBUE has achieved meaningful patient growth for the first time since the second quarter of 2024, serving more patients this quarter than in any prior quarter, and NUPLAZID continues to drive strong momentum from the direct-to-consumer campaign launched last year.
• She also mentioned the company's commitment to expand the DAYBUE franchise globally and the recent service of the first patient outside the U.S. through their managed access program in the European Union.
• She expressed excitement about the accelerated timeline for the COMPASS PWS Phase 3 study of ACP-101 and the upcoming R&D Day.

Industry Context

Acadia's focus on neuroscience and neuro-rare diseases positions it within a growing market for targeted therapies. The company's success with NUPLAZID and DAYBUE demonstrates its ability to develop and commercialize innovative treatments for unmet medical needs. The expansion into the EU market for DAYBUE is a significant step in broadening its global reach.

Comparison to Industry Standards

• Acadia's revenue growth of 19% year-over-year is competitive compared to other pharmaceutical companies in the neuroscience space.
• Companies like Biogen and Novartis, which also have significant neuroscience portfolios, have shown similar growth rates in specific product lines.
• The success of DAYBUE in the Rett syndrome market can be compared to the launch of other orphan drugs, where early adoption and patient growth are critical for long-term success.
• Acadia's R&D spending as a percentage of revenue is in line with industry averages for companies focused on clinical-stage development programs.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and growth prospects.
• Employees will benefit from the company's expansion and continued success.
• Patients will benefit from the availability of innovative treatments for neurological disorders.
• Healthcare professionals will have access to new treatment options for their patients.

Next Steps

• Acadia will continue to commercialize NUPLAZID and DAYBUE.
• The company will focus on expanding the DAYBUE franchise globally.
• Acadia will advance the COMPASS PWS Phase 3 study of ACP-101 and prepare for a potential New Drug Application submission.
• The company will share more details about its pipeline programs at its inaugural R&D Day next month.

Key Dates

Keywords

Acadia Pharmaceuticals, NUPLAZID, DAYBUE, Financial Results, Q1 2025, ACP-101, Prader-Willi Syndrome, Rett Syndrome, Revenue, Net Income